Breast Cancer Research and Treatment

, Volume 131, Issue 1, pp 27–31 | Cite as

The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk

  • Ke-Da Yu
  • Ao-Xiang Chen
  • Chen Yang
  • Lei Fan
  • A-Ji Huang
  • Zhi-Ming Shao
Preclinical study

Abstract

The association between single-nucleotide polymorphisms (SNPs) in the interleukin-10 (IL-10) gene promoter and breast cancer risk is still ambiguous. We here performed a meta-analysis based on the evidence currently available from the literature to make a more precise estimation of the relationship between two genetic variants in the IL-10 gene promoter, −1082A > G (rs1800896) and −592C > A (rs1800872), and breast cancer. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding strengths of association under the codominant, dominant, and recessive models. A total of ten studies (4,181 cases and 4,384 controls) were eligible for meta-analysis. There were six studies with 3,032 cases and 3,190 controls for rs1800872, and eight studies with 1,636 cases and 1,670 controls for rs1800896. Meta-analysis showed that neither of the two polymorphisms had any association with increased breast cancer risk (for rs1800896: OR = 1.060, 95% CI = 0.785–1.432 in the dominant model, and OR = 1.152, 95% CI = 0.958–1.386 in the recessive model; and for rs1800872: OR = 0.952, 95% CI = 0.859–1.056 in the dominant model, and OR = 0.892, 95% CI = 0.741–1.072 in the recessive model). The results did not change when the analyses were restricted in Caucasians, or in the studies fulfilling Hardy–Weinberg equilibrium, or according to source of controls. In outlier analysis, no individual study affected the overall OR dominantly, since omission of any single study made no material huge difference. In conclusion, the present meta-analysis suggests a lack of association between the two SNPs (rs1800896 and rs1800872) in the IL-10 gene promoter and breast cancer risk. Further studies, either with larger sample size or regarding other SNPs/haplotypes within the IL-10 gene, are needed to clarify the role of IL-10 in breast carcinogenesis.

Keywords

Interleukin-10 rs1800896 rs1800872 Breast cancer Meta-analysis 

Notes

Acknowledgments

This research is supported by grants from the National Basic Research Program of China (2006CB910501), 2009 Youth Foundation of Shanghai Public Health Bureau, 2009 Youth Foundation of Shanghai Medical College, and the National Natural Science Foundation of China (30971143, 30972936).

Conflict of interest

All authors declared no potential conflicts of interest.

References

  1. 1.
    Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. New Engl J Med 358:2796–2803PubMedCrossRefGoogle Scholar
  2. 2.
    Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. Jama 299:2423–2436PubMedCrossRefGoogle Scholar
  3. 3.
    Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205–218PubMedCrossRefGoogle Scholar
  4. 4.
    Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55:543–547PubMedCrossRefGoogle Scholar
  5. 5.
    Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293PubMedCrossRefGoogle Scholar
  6. 6.
    Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E (2008) Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 44:1093–1099PubMedCrossRefGoogle Scholar
  7. 7.
    Howell WM, Rose-Zerilli MJ (2007) Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137:194S–199SPubMedGoogle Scholar
  8. 8.
    Merendino RA, Arena A, Capozza AB, Chillemi S, Mesiti M (1996) Serum levels of interleukin-10 in patients affected by breast cancer. Immunol Lett 53:59–60PubMedCrossRefGoogle Scholar
  9. 9.
    Yu KD, Di GH, Yuan WT, Fan L, Wu J, Hu Z, Shen ZZ, Zheng Y, Huang W, Shao ZM (2009) Functional polymorphisms, altered gene expression and genetic association link NRH: quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet 18:2502–2517PubMedCrossRefGoogle Scholar
  10. 10.
    Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P (1999) Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42:1101–1108PubMedCrossRefGoogle Scholar
  11. 11.
    Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8PubMedCrossRefGoogle Scholar
  12. 12.
    Economopoulos KP, Sergentanis TN (2010) Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Tr 120:211–216CrossRefGoogle Scholar
  13. 13.
    Sergentanis TN, Economopoulos KP (2010) GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Tr 121:195–202CrossRefGoogle Scholar
  14. 14.
    Li N, Dong J, Hu Z, Shen H, Dai M (2010) Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Tr 121:177–184CrossRefGoogle Scholar
  15. 15.
    Yu KD, Di GH, Fan L, Chen AX, Yang C, Shao ZM (2010) Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Tr 122:483–488CrossRefGoogle Scholar
  16. 16.
    Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, Shao ZM (2010) Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Tr 122:251–257CrossRefGoogle Scholar
  17. 17.
    Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM (2009) A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J 23:2274–2287PubMedCrossRefGoogle Scholar
  18. 18.
    Wittke-Thompson JK, Pluzhnikov A, Cox NJ (2005) Rational inferences about departures from Hardy–Weinberg equilibrium. Am J Hum Genet 76:967–986PubMedCrossRefGoogle Scholar
  19. 19.
    Yu KD, Di GH, Fan L, Shao ZM (2009) Test of Hardy–Weinberg equilibrium in breast cancer case–control studies: an issue may influence the conclusions. Breast Cancer Res Tr 117:675–677CrossRefGoogle Scholar
  20. 20.
    Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2005) Benign breast disease and the risk of breast cancer. New Engl J Med 353:229–237PubMedCrossRefGoogle Scholar
  21. 21.
    Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A (2003) Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 49:1664–1667PubMedCrossRefGoogle Scholar
  22. 22.
    Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173PubMedCrossRefGoogle Scholar
  23. 23.
    Guzowski D, Chandrasekaran A, Gawel C, Palma J, Koenig J, Wang XP, Dosik M, Kaplan M, Chu CC, Chavan S, Furie R, Albesiano E, Chiorazzi N, Goodwin L (2005) Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech 16:154–166PubMedGoogle Scholar
  24. 24.
    Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188PubMedCrossRefGoogle Scholar
  25. 25.
    Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H (2006) SNP–SNP interactions in breast cancer susceptibility. BMC Cancer 6:114PubMedCrossRefGoogle Scholar
  26. 26.
    Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C, Accardo A, Verna R, Candore G, Caruso C, Lio D, Palmeri S (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109PubMedCrossRefGoogle Scholar
  27. 27.
    Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O (2007) Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28:1728–1733PubMedGoogle Scholar
  28. 28.
    Kong F, Liu J, Liu Y, Song B, Wang H, Liu W (2010) Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 29:72PubMedCrossRefGoogle Scholar
  29. 29.
    Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, Wascher TC, Paulweber B, Samonigg H (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Tr 90:113–115CrossRefGoogle Scholar
  30. 30.
    Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Ke-Da Yu
    • 1
    • 2
  • Ao-Xiang Chen
    • 1
    • 2
  • Chen Yang
    • 1
    • 2
  • Lei Fan
    • 1
    • 2
  • A-Ji Huang
    • 1
    • 2
  • Zhi-Ming Shao
    • 1
    • 2
    • 3
  1. 1.Department of Breast Surgery, Cancer Center/Cancer InstituteFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Institutes of Biomedical ScienceFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations